Should aspirin be discontinued prior to a nasal mass biopsy, and if so, how many days before the procedure?

Aspirin Does NOT Need to Be Stopped for Nasal Mass Biopsy

For a nasal mass biopsy, aspirin should be continued without interruption. This is a low-risk procedure where the bleeding risk from continuing aspirin is minimal and does not outweigh the thrombotic risk of stopping it, particularly in patients on aspirin for secondary cardiovascular prevention.

Risk Stratification of Nasal Biopsy

A nasal mass biopsy is classified as a low-bleeding-risk procedure based on established procedural hierarchies. The 2021 BSG/ESGE guidelines 1 explicitly categorize "diagnostic procedures +/- biopsy" as low-risk procedures, which includes mucosal biopsies. While these guidelines focus on endoscopic procedures, the bleeding risk profile of a simple nasal mucosal biopsy is comparable or lower than gastrointestinal mucosal biopsies.

Evidence for Continuing Aspirin

Guideline Recommendations

The most relevant guidance comes from multiple high-quality sources:

• For low-risk procedures, aspirin continuation is strongly recommended 1. The 2021 BSG/ESGE guidelines state that for low-risk endoscopic procedures (which includes diagnostic procedures with biopsy), aspirin should be continued.

• The 2012 ACCP guidelines 2 recommend continuing aspirin for patients at moderate to high cardiovascular risk undergoing noncardiac surgery, and specifically state that aspirin should be continued for minor dental and dermatologic procedures.

• The 2020 BSG liver biopsy guidelines 3 note that stopping aspirin 3 days prior to percutaneous biopsy "should be considered" but emphasize this decision depends on the indications for aspirin and urgency of the biopsy. Importantly, they note that empirical experience suggests pausing aspirin may not be necessary and should be at the operator's discretion if urgent.

Research Evidence

High-quality research supports aspirin continuation for low-risk biopsies:

• A large retrospective study of 15,181 percutaneous biopsies 4 found that aspirin use within 10 days before biopsy resulted in a bleeding rate of only 0.6% versus 0.4% in non-aspirin users (p=0.34, not statistically significant).

• A more recent study of 30,333 biopsies 5 found that aspirin use within 10 days showed only a trend toward increased bleeding (OR 1.5,95% CI 0.96-2.3, p=0.08), which was not statistically significant. Critically, increased bleeding risk was only significant when aspirin was taken on the day of the procedure (OR 6.6, p<0.001).

• A prospective study of bone and soft tissue biopsies 6 found zero bleeding complications in 332 patients who continued NSAIDs/aspirin, demonstrating safety of continuation.

Algorithm for Decision-Making

Continue Aspirin If:

• Patient is on aspirin for secondary prevention (history of MI, stroke, TIA, coronary stents, peripheral vascular disease, or cerebrovascular disease) - ALWAYS continue 1, 2
• Patient is on aspirin for primary prevention in high-risk individuals (diabetes, multiple cardiovascular risk factors) - strongly consider continuing
• The biopsy is truly needed and cannot be delayed

Consider Brief Hold (3 days maximum) Only If:

• Patient is on aspirin for primary prevention only in low-risk individuals
• Patient has additional bleeding risk factors (thrombocytopenia, coagulopathy, concurrent anticoagulation)
• The ENT surgeon has specific anatomic concerns about the biopsy site (highly vascular tumor, proximity to major vessels)

Never Stop Aspirin If:

• Patient has coronary stents (especially drug-eluting stents within 12 months or bare-metal stents within 1 month) 7
• Recent acute coronary syndrome (within 3 months)
• Recent stroke/TIA (within 3 months)

Critical Pitfalls to Avoid

1. Do not confuse aspirin with P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor). P2Y12 inhibitors DO require 5-7 days discontinuation for higher-risk procedures 1, 8, but aspirin should be continued even when stopping the P2Y12 inhibitor.

2. The thrombotic risk of stopping aspirin far exceeds the minimal bleeding risk of a nasal biopsy, particularly for secondary prevention. The 2021 BSG/ESGE guidelines 1 explicitly state that "aspirin for secondary prevention should not be routinely stopped."

3. If aspirin must be held, the maximum duration should be 3 days 3, not the 5-7 days often requested. Platelet function normalizes within 96 hours 9, but cardiovascular risk increases immediately upon cessation.

4. Same-day aspirin increases bleeding risk significantly 5. If any compromise is needed, simply hold the morning dose on the day of the procedure and resume that evening.

Practical Recommendation

Inform the ENT surgeon that current evidence-based guidelines support continuing aspirin for low-risk mucosal biopsies. If the surgeon remains concerned, offer this compromise: hold only the morning dose on the day of the procedure and resume aspirin that evening. This minimizes both bleeding and thrombotic risk. For patients on aspirin for secondary prevention, document that the cardiovascular risk of stopping aspirin outweighs the minimal bleeding risk of this procedure, and aspirin should be continued throughout the perioperative period.